Trials / Completed
CompletedNCT04257617
A Trial of ZL-1201 in Subjects With Advanced Cancer
First in Human, Phase I Trial of ZL-1201 in Subjects With Advanced Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Zai Lab (Shanghai) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
First in Human, Phase I Trial of ZL-1201 in Subjects with Advanced Cancer
Detailed description
This is a first-in-human, dose escalation trial of ZL-1201. The major aims of the study are to define the safety profile of this new drug, and to determine a recommended dose and schedule for potential additional trials.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZL-1201 | Part 1 \& 2: Escalating dose of ZL-1201, Part 3: three dose levels determined from Part 1 and Part 2. |
Timeline
- Start date
- 2020-05-11
- Primary completion
- 2022-05-17
- Completion
- 2023-01-19
- First posted
- 2020-02-06
- Last updated
- 2023-08-22
Locations
7 sites across 2 countries: United States, China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04257617. Inclusion in this directory is not an endorsement.